Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland

Objective : The objective of the study was to analyse the prevalence of psoriatic arthritis (PsA) in Poland and to assess the costs generated by treatment of PsA patients in the system of public healthcare. Material and methods : The analysis was based on the database of the public payer, the Nati...

Full description

Bibliographic Details
Main Authors: Filip Raciborski, Andrzej Śliwczyński, Anna Kłak, Brygida Kwiatkowska, Melania Brzozowska, Małgorzata Tłustochowicz
Format: Article
Language:English
Published: Termedia Publishing House 2016-12-01
Series:Rheumatology
Subjects:
Online Access:https://www.termedia.pl/Prevalence-of-psoriatic-arthritis-and-costs-generated-by-treatment-of-psoriatic-arthritis-patients-in-the-public-health-system-the-case-of-Poland,18,29022,1,1.html
id doaj-14a7a4e02070474bbbccc2e804825610
record_format Article
spelling doaj-14a7a4e02070474bbbccc2e8048256102020-11-25T00:11:55ZengTermedia Publishing HouseRheumatology0034-62332084-98342016-12-0154627828410.5114/reum.2016.6490229022Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of PolandFilip RaciborskiAndrzej ŚliwczyńskiAnna KłakBrygida KwiatkowskaMelania BrzozowskaMałgorzata TłustochowiczObjective : The objective of the study was to analyse the prevalence of psoriatic arthritis (PsA) in Poland and to assess the costs generated by treatment of PsA patients in the system of public healthcare. Material and methods : The analysis was based on the database of the public payer, the National Health Fund (NFZ). PsA was defined by the diagnostic ICD-10 codes M07 (Enteropathic arthropathies) and L40.5 (Psoriatic arthropathies). The estimate of the costs was based on the reports submitted to the NFZ by health service providers. The prevalence rates were calculated using the NFZ data and the population estimates from the Central Statistical Office of Poland (GUS). Results : In 2015, the prevalence of PsA (ICD-10: L40.5 and M07) in Poland was 3.2 per 10 000 population (3.7 in women and 2.6 in men). In 2015, nearly 7.3 thousand patients with the diagnosis of M07 and 6.3 thousand patients with the diagnosis of L40.5 received healthcare benefits. Women accounted for 60.6% of those patients. Nearly three fourths of PsA patients were aged 40 to 69 years with the median age of 54 years (56 years in women and 50 years in men). Between 2008 and 2015 the NFZ expenditure on the treatment of PsA increased from 6.6 million Polish zloty (PLN) (1.9 million EUR) to PLN 50.8 million (12.1 million EUR). In the same period, the number of PsA patients increased from 3.4 thousand to 11.9 thousand. In 2015, the mean cost of treatment per PsA patient was PLN 3.8 thousand. Conclusions : The PsA prevalence rates estimated by the authors from the NFZ database are clearly lower than those derived from studies in other European countries, which may suggest that the actual number of PsA patients in Poland may be underestimated. Still the number of patients treated for PsA increased nearly 3.5-fold during 2008–2015, when the cost of PsA treatment rose more than 7 times.https://www.termedia.pl/Prevalence-of-psoriatic-arthritis-and-costs-generated-by-treatment-of-psoriatic-arthritis-patients-in-the-public-health-system-the-case-of-Poland,18,29022,1,1.htmlpsoriatic arthritis epidemiology increasing costs of treatment
collection DOAJ
language English
format Article
sources DOAJ
author Filip Raciborski
Andrzej Śliwczyński
Anna Kłak
Brygida Kwiatkowska
Melania Brzozowska
Małgorzata Tłustochowicz
spellingShingle Filip Raciborski
Andrzej Śliwczyński
Anna Kłak
Brygida Kwiatkowska
Melania Brzozowska
Małgorzata Tłustochowicz
Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
Rheumatology
psoriatic arthritis
epidemiology
increasing costs of treatment
author_facet Filip Raciborski
Andrzej Śliwczyński
Anna Kłak
Brygida Kwiatkowska
Melania Brzozowska
Małgorzata Tłustochowicz
author_sort Filip Raciborski
title Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
title_short Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
title_full Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
title_fullStr Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
title_full_unstemmed Prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of Poland
title_sort prevalence of psoriatic arthritis and costs generated by treatment of psoriatic arthritis patients in the public health system – the case of poland
publisher Termedia Publishing House
series Rheumatology
issn 0034-6233
2084-9834
publishDate 2016-12-01
description Objective : The objective of the study was to analyse the prevalence of psoriatic arthritis (PsA) in Poland and to assess the costs generated by treatment of PsA patients in the system of public healthcare. Material and methods : The analysis was based on the database of the public payer, the National Health Fund (NFZ). PsA was defined by the diagnostic ICD-10 codes M07 (Enteropathic arthropathies) and L40.5 (Psoriatic arthropathies). The estimate of the costs was based on the reports submitted to the NFZ by health service providers. The prevalence rates were calculated using the NFZ data and the population estimates from the Central Statistical Office of Poland (GUS). Results : In 2015, the prevalence of PsA (ICD-10: L40.5 and M07) in Poland was 3.2 per 10 000 population (3.7 in women and 2.6 in men). In 2015, nearly 7.3 thousand patients with the diagnosis of M07 and 6.3 thousand patients with the diagnosis of L40.5 received healthcare benefits. Women accounted for 60.6% of those patients. Nearly three fourths of PsA patients were aged 40 to 69 years with the median age of 54 years (56 years in women and 50 years in men). Between 2008 and 2015 the NFZ expenditure on the treatment of PsA increased from 6.6 million Polish zloty (PLN) (1.9 million EUR) to PLN 50.8 million (12.1 million EUR). In the same period, the number of PsA patients increased from 3.4 thousand to 11.9 thousand. In 2015, the mean cost of treatment per PsA patient was PLN 3.8 thousand. Conclusions : The PsA prevalence rates estimated by the authors from the NFZ database are clearly lower than those derived from studies in other European countries, which may suggest that the actual number of PsA patients in Poland may be underestimated. Still the number of patients treated for PsA increased nearly 3.5-fold during 2008–2015, when the cost of PsA treatment rose more than 7 times.
topic psoriatic arthritis
epidemiology
increasing costs of treatment
url https://www.termedia.pl/Prevalence-of-psoriatic-arthritis-and-costs-generated-by-treatment-of-psoriatic-arthritis-patients-in-the-public-health-system-the-case-of-Poland,18,29022,1,1.html
work_keys_str_mv AT filipraciborski prevalenceofpsoriaticarthritisandcostsgeneratedbytreatmentofpsoriaticarthritispatientsinthepublichealthsystemthecaseofpoland
AT andrzejsliwczynski prevalenceofpsoriaticarthritisandcostsgeneratedbytreatmentofpsoriaticarthritispatientsinthepublichealthsystemthecaseofpoland
AT annakłak prevalenceofpsoriaticarthritisandcostsgeneratedbytreatmentofpsoriaticarthritispatientsinthepublichealthsystemthecaseofpoland
AT brygidakwiatkowska prevalenceofpsoriaticarthritisandcostsgeneratedbytreatmentofpsoriaticarthritispatientsinthepublichealthsystemthecaseofpoland
AT melaniabrzozowska prevalenceofpsoriaticarthritisandcostsgeneratedbytreatmentofpsoriaticarthritispatientsinthepublichealthsystemthecaseofpoland
AT małgorzatatłustochowicz prevalenceofpsoriaticarthritisandcostsgeneratedbytreatmentofpsoriaticarthritispatientsinthepublichealthsystemthecaseofpoland
_version_ 1725402301816897536